11^th International Conference on COPD and Lungs November 22-23, 2021 Singapore City, Singapore

With members from round the world focused on learning about Pulmonary, Lung and respiratory illness and its advances; this is often your best opportunity to succeed in the most important assemblage of participants from the COPD, Pulmonary, Lung, and Respiratory community. Conduct presentations, distribute information, meet with current and potential scientists, Pulmonologists this conference will encourage innovative ideas and advanced diagnostic approaches towards COPD treatment and to approach Respiratory problems thanks to Covid-19. By bringing together the pulmonary community, Organizers presenting the newest developments, and identifying unmet treatment needs, COPD-2021 hopes to accelerate research in COPD, improving patient outcomes. It'll share recent advancements and knowledge share about the Pulmonary, Critical Care Medicine, Lung, Asthma, Pneumonia and Respiratory treatment strategies. The participant companies can display their product to realize the networks and to market their upcoming new strategies and exchange the ideas for the longer term era.

• COPD Faculty
• COPD Students, Scientists
• Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
• Pulmonologists
• COPD Researchers
• COPD Associations and Societies
• Business Entrepreneurs
• Directors/Managers
• Young Researchers
• Pulmonology Pharma Companies
• Medical Colleges
• Manufacturing Medical Devices Companies
• Laboratory Technicians
• Pharmaceutical Companies and Industries
• Training Institutes
• Pulmonary Medicine and surgery related Companies

• Chronic Obstructive Pulmonary Disease (COPD)
• Chronic Bronchitis
• Emphysema
• Asthama
• Pulmonary Arterial Hypertension
• Pneumonia
• Cystic Fibrosis
• Coronavirus (COVID-19)
• Lung Cancer
• Interventional pulmonology
• Respiratory Tract Infections
• Stages & Severity on Lung Diseases
• COPD Health Care

The Global Burden of Disease Study reports a prevalence of 251 million cases of COPD globally in 2016. Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year). More than 90% of COPD deaths occur in low­ and middle income countries.

Industry based studies of COPD have found an increased risk in textile mills, the rubber industry, mining, construction, chemical production, food products manufacturing, and agriculture. The US Work-Related Lung Disease Surveillance Report lists industries related to significantly elevated proportional mortality ratios for COPD. In support of our findings, the proportional mortality ratios for taxicab services, trucking services, automotive and miscellaneous repair services, construction, gasoline service stations, and therefore the military were among the very best. On the opposite hand, mining and potteries, which had the very best proportional mortality ratios listed within the Work-Related Lung Disease Surveillance Report.

According to a search report by Research and Markets, the market price of COPD in 2018 was approximately US$10.9 billion, with a compound annual rate of growth (CAGR) of roughly 5.9%, and it's expected to succeed in US$19.3 billion in 2028. Among them, the US market accounts for about 40% of the COPD market and developed regions like Europe and Japan account for 18% and 9.2% respectively. In China, the COPD drug market has developed steadily in recent years. Consistent with PDB data, the domestic Chinese COPD market in 2018 is RMB 2.2 billion (approximately US$324 million). The compound rate of growth reached 15.56%. The rapid climb of the COPD market is especially thanks to the increasing incidence of COPD worldwide, but the explanation for COPD varies by geographical area.

According to the worldwide Burden of Disease Research Report, there have been 251 million cases of chronic obstructive pulmonary disease worldwide in 2016, and a mean of 1 person died of COPD every 10 seconds. Additionally, COPD features an extended course, and patients often need frequent medical visits and hospitalization and long-term care because of acute exacerbations, which consumes plenty of medical resources. It’s become a thorny global disease burden, and it's attracted more and more attention from scientists, pharmaceutical companies, and investors.

A lack of funding for research into chronic obstructive pulmonary disease, also as difficulties in conducting clinical trials, make finding new treatments for this respiratory condition challenging. But there are glimmers of hope, like reversing steroid resistance and identifying subpopulations of patients so on hurry up clinical trials.